ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Vogelzang on XL184's Effect on Bone Metastases

Nicholas J. Vogelzang, MD
Published: Thursday, Jun 16, 2011

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada on cabozantinib's (XL184) effect on bone metastases.

Dr. Vogelzang says some cancers are more likely than others to spread to the bone. Prostate cancer is the premier example of this, with over 90% of patients having bone metastases. Melanoma, lung cancer and breast cancer have lower but consistent rates of bone metastases. With cabozantinib, somewhere between 60% and 90% of the patients had improvement in the bone scan, improvement in bone pain, improvement in reduced pain and reduction in need for pain medicine.
Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada on cabozantinib's (XL184) effect on bone metastases.

Dr. Vogelzang says some cancers are more likely than others to spread to the bone. Prostate cancer is the premier example of this, with over 90% of patients having bone metastases. Melanoma, lung cancer and breast cancer have lower but consistent rates of bone metastases. With cabozantinib, somewhere between 60% and 90% of the patients had improvement in the bone scan, improvement in bone pain, improvement in reduced pain and reduction in need for pain medicine.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x